Abstract
The use of combined-modality therapy — doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) plus involved-field radiation therapy (IFRT) — yields a high cure rate for patients with stage I or II Hodgkin lymphoma (HL). However, each of these modalities poses risks for acute and delayed toxicities. At the American Society of Hematology 2009 meeting, the German Hodgkin Study Group reported preliminary results of a multicenter trial (HD10) showing that therapy de-escalation minimized treatment-related complications yet retained high cure rates in early-stage HL …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
